CG Oncology, Inc.
CGON
$19.28
$1.659.36%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 960.47% | -61.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 960.47% | -61.26% | |||
| Cost of Revenue | 36.58% | 6.24% | |||
| Gross Profit | -34.55% | -6.65% | |||
| SG&A Expenses | 34.29% | 16.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.88% | 9.14% | |||
| Operating Income | -34.47% | -9.45% | |||
| Income Before Tax | -55.83% | -7.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -55.83% | -7.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -55.83% | -7.95% | |||
| EBIT | -34.47% | -9.45% | |||
| EBITDA | -34.57% | -9.39% | |||
| EPS Basic | -51.53% | -7.16% | |||
| Normalized Basic EPS | -51.55% | -7.11% | |||
| EPS Diluted | -51.53% | -7.16% | |||
| Normalized Diluted EPS | -51.55% | -7.11% | |||
| Average Basic Shares Outstanding | 2.84% | 0.74% | |||
| Average Diluted Shares Outstanding | 2.84% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
